Foresite Capital Opportunity Management V’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Foresite Capital Opportunity Management V’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.48M	Hold	291,667	–	–	10.46%	5
2022 Q2	$3.68M	Hold	291,667	–	–	9.27%	5
2022 Q1	$3.28M	Hold	291,667	–	–	4.6%	8
2021 Q4	$5.17M	Buy	+291,667	New	+$6.15M	3.46%	7

Other funds holding KNTE

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Foresite Capital Opportunity Management V's KNTE Position: Q3 2022 in Review

Foresite Capital Opportunity Management V held its Kinnate Biopharma Inc. Common Stock (KNTE) position steady in Q3 2022 at 291,667 shares worth $3.48M. The position accounts for 10.46% of the portfolio, ranked #5.

Foresite Capital Opportunity Management V first reported a position in KNTE in Q4 2021 and has held it in 4 quarters since. The position peaked at $5.17M in Q4 2021. 84 funds tracked by Wall St. Rank hold KNTE as of Q3 2022.

Foresite Capital Opportunity Management V held 291,667 shares of Kinnate Biopharma Inc. Common Stock worth $3.48M as of Q3 2022.
Foresite Capital Opportunity Management V left its Kinnate Biopharma Inc. Common Stock share count unchanged in Q3 2022.
Kinnate Biopharma Inc. Common Stock made up 10.46% of Foresite Capital Opportunity Management V's portfolio in Q3 2022, its #5 holding.
Foresite Capital Opportunity Management V first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2021 and has held it in 4 quarters since.
Foresite Capital Opportunity Management V's Kinnate Biopharma Inc. Common Stock position peaked at $5.17M in Q4 2021.
84 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2022.

Based on Foresite Capital Opportunity Management V's 13F filing for Q3 2022, filed 14 Nov 2022.